Pulmatrix Inc. Updates: Focus on Chronic Respiratory Disease Therapies

Pulmatrix, Inc., a clinical-stage biotechnology company based in Lexington, United States, continues to make strides in the health care sector, particularly within the pharmaceutical industry. The company is dedicated to developing innovative therapies aimed at treating chronic respiratory diseases, including cystic fibrosis, obstructive pulmonary disease, and idiopathic pulmonary fibrosis. These efforts are part of Pulmatrix’s broader mission to serve patients across the country with cutting-edge medical solutions.

As of May 6, 2025, Pulmatrix’s stock is trading on the Nasdaq exchange at a close price of $6.29. This figure reflects a significant fluctuation over the past year, with the stock reaching a 52-week high of $10.40 on February 17, 2025, and a 52-week low of $1.72 on May 28, 2024. The company’s market capitalization currently stands at approximately $23,828,570 USD.

Pulmatrix’s focus on chronic respiratory diseases positions it as a key player in the pharmaceutical industry, addressing some of the most challenging health conditions affecting millions of individuals. The company’s commitment to innovation and patient care is evident in its ongoing research and development efforts.

For more information about Pulmatrix, Inc., including detailed insights into their therapies and patient services, interested parties are encouraged to visit their official website at www.Pulmatrix.com .